Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics (NASDAQ:HALO) from $12.00 to $16.00 in a note issued to investors on Thursday. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.’s price objective suggests a potential upside of 27.80% from the stock’s previous close.
Halozyme Therapeutics (NASDAQ:HALO) traded up 11.18% during mid-day trading on Thursday, hitting $13.92. 4,138,157 shares of the company’s stock traded hands. Halozyme Therapeutics has a 52 week low of $6.88 and a 52 week high of $18.18. The stock’s 50-day moving average is $8.96 and its 200-day moving average is $9.28. The company’s market cap is $1.727 billion.
Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 10th. The company reported ($0.16) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.14) by $0.02. The company had revenue of $14.60 million for the quarter, compared to the consensus estimate of $16.50 million. During the same quarter in the prior year, the company posted ($0.17) earnings per share. The company’s quarterly revenue was down 8.8% on a year-over-year basis. On average, analysts predict that Halozyme Therapeutics will post $-0.63 earnings per share for the current fiscal year.
Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray raised their price target on shares of Halozyme Therapeutics to $17.00 in a research note on Thursday. Separately, analysts at MLV & Co
initiated coverage on shares of Halozyme Therapeutics in a research note on Friday, January 2nd. They set a “buy” rating and a $15.00 price target on the stock. Finally, analysts at MLV & Co
initiated coverage on shares of Halozyme Therapeutics in a research note on Wednesday, December 24th. They set a “buy” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Halozyme Therapeutics presently has a consensus rating of “Buy” and an average target price of $12.91.
Halozyme Therapeutics, Inc is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix.
http://tickerreport.com/banking-finance/381889/jpmorgan-chase-co-raises-halozyme-therapeutics-price-target-to-16-00-halo/